**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Sara Oubari, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

**Main Body of the Abstract**
Introduction
Plasma cell dyscrasias are the most common cause of light-chain amyloidosis (AL). Interphase Fluorescence in situ Hybridization (iFISH) is an essential method to categorize and assess the treatment approach in multiple myeloma. In this retrospective study, we aim to evaluate the prognostic role of iFISH in AL.
Methods
Patients with confirmed AL and available iFISH (n = 149) presented between 2015 and 2023 at our center were included. Aberrations detectable in more than 20% of patients were analyzed, with a threshold of 10% applied for gains, losses and translocations. Fisher´s exact test and Kaplan-Meier survival analysis were used.
Results
Overall, at least one aberration was detectable in 94% of patients. Cardiac involvement was present in 90% of patients with available iFISH. We found rearrangement 14q32 in 62%, t(11;14) in 56%, Del13q14 in 38%, gain 11q22 in 36%, gain 9q22 in 26%, gain 1q21 in 23% and gain 15q22 in 20%. Patients with gain 1q21 showed high dFLC (median 622 vs. 203 mg/l, p=0.007), elevated NTproBNP (median 9945 vs. 3507 pg/ml, p=0.03), hsTNT (median 90 vs. 52, p=0.04) and a worse overall survival after a median follow-up time of 32 months (HR 2.17, 95%CI 0.94-5.02, p=0.01). Except for a significant dFLC-increase in t(11;14), no significant effects on cardiac biomarkers or survival were observed in all other aberrations.
Conclusion
Our data highlight the adverse impact of gain 1q21 on overall survival in AL demonstrated by increased levels of dFLC and cardiac biomarkers. Further studies are warranted to validate these findings.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Sara Oubari, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

**Main Body of the Abstract**
**Introduction**
Plasma cell dyscrasias are the most common cause of light-chain amyloidosis (AL). Interphase Fluorescence in situ Hybridization (iFISH) is an essential method to categorize and assess the treatment approach in multiple myeloma. In this retrospective study, we aim to evaluate the prognostic role of iFISH in AL.
**Methods**
Patients with confirmed AL and available iFISH (_n_ = 149) presented between 2015 and 2023 at our center were included. Aberrations detectable in more than 20% of patients were analyzed, with a threshold of 10% applied for gains, losses and translocations. Fisher´s exact test and Kaplan-Meier survival analysis were used.
**Results**
Overall, at least one aberration was detectable in 94% of patients. Cardiac involvement was present in 90% of patients with available iFISH. We found rearrangement 14q32 in 62%, t(11;14) in 56%, Del13q14 in 38%, gain 11q22 in 36%, gain 9q22 in 26%, gain 1q21 in 23% and gain 15q22 in 20%. Patients with gain 1q21 showed high dFLC (median 622 vs. 203 mg/l, _p=_0.007), elevated NTproBNP (median 9945 vs. 3507 pg/ml, _p=_0.03), hsTNT (median 90 vs. 52, _p=_0.04) and a worse overall survival after a median follow-up time of 32 months (HR 2.17, 95%CI 0.94-5.02, _p=_0.01). Except for a significant dFLC-increase in t(11;14), no significant effects on cardiac biomarkers or survival were observed in all other aberrations.
**Conclusion**
Our data highlight the adverse impact of gain 1q21 on overall survival in AL demonstrated by increased levels of dFLC and cardiac biomarkers. Further studies are warranted to validate these findings.



Clinical implications of genetic interphase fluorescence in situ hybridization aberrations in systemic light chain amyloidosis PA134 (#494)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.